What We Do

Funding Research


October 2022

$100,000 Award to Patton Lab

We’re pleased to announce a $100,000 research donation to the University of Edinburgh – Patton Lab – to develop zebrafish models of CLOVES.   

Dr. Hannah Brunsdon has written a lay summary about this project below.

“People with CLOVES syndrome commonly have fatty growths, abnormal formation of blood vessels and lymphatics, dark skin lesions, and alterations in growth of some bones, among other problems. These changes are detectable from birth and often progress, causing increasing health problems during childhood and beyond. CLOVES syndrome is caused by changes that arise spontaneously in the very earliest stages of life. These affect the PIK3CA gene, causing it to become hyperactive. This causes increases in growth signals in affected tissues, leading to patchy, poorly controlled growth of cells carrying the PIK3CA mutation.

Laboratory studies of cells or animals carrying the CLOVES mutations in PIK3CA have already increased our understanding of the development of CLOVES syndrome, and are helping to guide new treatment strategies. However, CLOVES syndrome is unusually complex to mimic for these studies, because there is a mixture of healthy and PIK3CA-altered cells in affected people, the gene changes arise randomly after conception instead of being inherited, and changes can occur in a wide variety of different cells and tissues. This is why CLOVES syndrome shows itself very differently from person to person.

In this project, we aim to develop zebrafish as a new, clinically relevant animal model of CLOVES syndrome. Despite differences in their appearance to us, zebrafish are well established as models for human disease, with at least 70% of human disease-causing genes having zebrafish counterparts. Zebrafish breed rapidly, their genes can readily be altered, and development of key internal tissues and organs can be observed directly from the first cell divisions to adulthood. This means that, uniquely, events occurring during CLOVES syndrome development in a fish can be followed at the cellular level, in real time.

We plan to ‘edit’ zebrafish Pik3ca using CRISPR-Cas9 technology to introduce the main CLOVES syndrome mutation alongside the normal gene. We will use fluorescent markers to watch the behaviour of Pik3ca-mutant cells and their interactions with surrounding normal cells. In this way, we will be able to capture the earliest events that cause clinical problems in people, and watch the onset and progression of CLOVES syndrome in a living intact animal, investigating whether there is a critical developmental time window for developing CLOVES. We believe this approach will allow us to model CLOVES syndrome at a higher resolution than possible in other animal models so far, and provides a stepping stone to using this model to screen for new therapies to treat CLOVES syndrome.”

May 2022

$50,000 Award to Dr. Wen Yi Aw

The Scientific and Medical Advisory Board and Board of Directors of CLOVES Syndrome Community are pleased to award Dr. Wen Yih Aw of The University of North Carolina/Chapel Hill a $50,000 grant for her project titled “Non-canonical signaling and therapeutic targets for vascular anomalies in CLOVES.”

Dr. Aw has provided a summary of her project for our community below.  Thank you Dr. Aw!

A characteristic condition of CLOVES is the development of vascular malformations, abnormal blood vessels that do not allow the proper transport of blood, nutrients, and oxygen. Improved treatment of CLOVES thus requires a better understanding of how vascular malformations develop and what genes and proteins can be targeted to revert vascular malformations to healthy, normal vasculature. However, it is difficult to study vascular malformations because the current experimental toolset is limited: mice have different genes and proteins that govern key processes in vascular development, and it is difficult to induce vascular malformations at a time and place that allows for well-controlled experiments, while traditional cultures of human cells do not form vessels. We have sought to address these shortcomings by developing a tissue engineered model of blood vessels using human cells. We have shown this micro-scale model of vascular physiology (microphysiological model) reproduces the development of vascular malformations when using cells that express a mutant version of the gene that leads to CLOVES, PIK3CA. In this project, we are going to test two drugs that have been used to treat other forms of vascular malformations and to treat certain cancers. Each drug inhibits a specific protein, so by testing these drugs in our microphysiological model, we can look at how inhibiting each protein affects individual cells and how the cells affect blood vessel formation. Thus, the results of our work will not only explore these drugs as treatments for vascular malformations in CLOVES but will also inform us about how vascular malformations arise, hopefully leading to the development of new drugs and interventions. Furthermore, by continuing to develop the microphysiological model, we will establish a platform for eventually testing drugs and personalized treatments for individual patients.

Microphysiological model of PIK3CA-driven vascular malformations reveals a role of dysregulated Rac1 and mTORC1/2 in lesion formation

September 2021

$25,000 Award to Professor Robert Semple

We are pleased to announce the second recipient of our 2021 Research Grant. 

Dr. Robert Semple will receive a $25,000 grant for the project titled “Human Pluripotent Stem Cells as a Model to Interrogate Pathogenesis and Developmental Origins of CLOVES”

This project will investigate human induced pluripotent stem cells (iPSCs) as a model system to examine the developmental origins of CLOVES, and to test new approaches to treatment.  iPSCs are made by “reprogramming” cells from biopsies of healthy adult volunteers.  They have the characteristics of true human embryonic cells, including the ability to turn into almost any cell type in the human body under the right conditions.  This means that these cells can be used in the lab to examine abnormal development and growth of all the tissues affected in CLOVES syndrome.  Crucially, only human cells are involved, which is important as mouse models do not perfectly mimic CLOVES when human mutations are introduced.  For this project, genetic “scissors” have already been used to introduce one or two CLOVES syndrome PIK3CA mutations to iPSCs.  The effect of these mutations on the ability of cells to make blood vessel and blood cells will first be examined, and then CLOVES will be mimicked by mixing different proportions of unaffected and CLOVES syndrome mutant cells.  Analysis will use advanced single cell sequencing techniques to assess the points in development where abnormalities occur, to assess whether the presence of cells with mutations affects the growth of healthy cells, and to assess the effects of drugs on the abnormalities observed.  The project will be a collaboration among scientists with expertise in CLOVES, in blood and blood vessel development, and in advanced statistical analysis of single cell sequencing studies.

Dr. Robert Semple
University of Edinburgh Centre for Cardiovascular Science
47 Little France Crescent
Edinburgh, EH16 4TJ, UK

May 2021 

$25,000 Award to Ana Angulo-Urarte 

Ana Angulo-Urarte received a $25,000 grant for the project titled “Identifying the molecular impact of PIK3CA variants in PROS towards stratification of patients and personalized medicine.” 

This research project will enhance the fundamental understanding of the physiological and molecular insight into PIK3CA-related overgrowth spectrum (PROS) and address fundamental biological questions concerning who (PiK3CA variant) and how (triggered mechanism) activating PIK3CA variants contribute to the development and severity of PROS conditions.

In April 2020, Ana joined the interdisciplinary team of Mariona Graupera to understand from the developmental and molecular point of view the broad presentation of PROS in patients using both patient samples and complex mice models. In February 2021, the group moved to the Josep Carreras Institute where Ana will drive the PROS research line in the lab of Dr. Graupera.  Please read Ana’s summary of this project below.

Thanks to the close collaboration between clinicians and researchers, we now know that a series of congenital overgrowth conditions, the so-called PIK3CA-related overgrowth spectrum (PROS), are caused by mutations in the PIK3CA gene. The critical mutations found in PIK3CA are not limited to a specific site but can span almost the entire gene.

With this grant, we want to explore whether different mutations able to activate PIK3CA may have an impact in the type and severity of disorder. It has been found that all PROS patients present, to some extent, the vasculature compartment affected. Therefore, we will select patient endothelial-derived cells, the ones lining the internal surface of blood vessels, as a model of study. In these cells, we will look for common and specific molecular and cellular features triggered by different mutations in PIK3CA.

This study will help to identify new biomarkers of PIK3CA-related signaling activation and, eventually, specific targets that can be used to develop personalized therapies in the future.

May 2021 

$10,000 Award to Dr. Bryan Sisk

We’re pleased to support Dr. Bryan Sisk, Assistant Professor of Pediatric Hematology and Oncology at Bioethics Research Center research study titled “Vascular anomalies communication” (VACOM) with a $10,000 grant.   Vascular anomalies are a group of rare disorders that can be disfiguring, painful, and even life-threatening. In our experiences, families affected by vascular anomalies have described multiple barriers to care and communication, such as difficulty accessing care from experts, persistent uncertainty about the diagnosis, and long-term consequences, insufficient information to guide decisions, and the necessity of persistent parental advocacy to ensure the child receives adequate medical care. However, no researchers have explored or categorized the needs or barriers experienced by these families.

We are performing a study that will incorporate interviews and surveys with caregivers and adult patients with vascular anomalies. In this 2-year study, we will learn about care and communication experiences from the patients’ and caregivers’ perspectives. We will also learn how these experiences affect quality of life and wellbeing. We will share our findings with the CLOVES community through interactive webinars at the beginning, middle, and end of the study. We will also share our results with clinicians and researchers who care for patients with vascular anomalies. These findings will be essential to develop future interventions to improve care and communication for these families. 

March 2020

$20,000 Award to Ralitsa Madsen

We awarded $20,000 to Dr. Ralitsa Madsen, postdoctoral fellow in Professor Bart Vanhaesebroeck’s research group at University College London Cancer Institute.  

Dr. Madsen, during her PhD in Professor Robert Semple’s group at Cambridge University, developed the first developmental cell models with PIK3CA-H1047R expression. This discovery has revised the prevailing understanding of how PIK3CA mutations may cause diseases such as PIK3CA Related Overgrowth Spectrum (PROS) and cancer, suggesting that it is not only important to know whether or not a mutation is present, but also its exact dose and thus the strength of PI3K pathway activation.

We’re supporting a project called “The systems biology of activating PIK3CA mutations in mosaic endothelial cell models.”  Diseases of human growth and development are often caused by genetic mutations that disrupt critical circuits inside our cells. Analogous to a broken radio, a cell affected by such a mutation no longer “plays the right music”. The PI3K circuit is one of the most commonly disrupted in cancer and developmental growth disorders known as PROS. Its disruption in PROS leads to unabated growth and a range of debilitating challenges. Despite available PI3K inhibitors, treatment of PROS remains limited, in part due to the diversity of cell types that can be affected – each one “playing the wrong tune” in its own unique way. A detailed understanding of these cells, and how to treat them, requires quantitative characterization of the malfunctioning circuit components. In addition, there is a need to understand whether diseased cells may influence, or even reprogram, healthy cells in a mosaic tissue to behave abnormally. This grant will support the engineering of novel cell model systems that enable studies addressing these critical questions.

February of 2019

$30,000 Award to Canaud Lab 

We awarded $30,000 to Canaud Lab for their continued work on CLOVES/PROS.  This award will be used for the creation of animal models to test PIK3CA inhibitors and to study PIK3CA related overgrowth physiopathology.  A note from Dr. Canaud to share with our supporters and community:

“Our group is so proud to be supported by the CLOVES Syndrome community. Thanks to you, we are making rapid and important progress on the understanding of the PIKC3A Related Overgrowth Syndrome physiopathology. We hope to share these results with you very soon. We express our gratitude to all the community.”

January 2018

$14,000 Award to Boston Children’s Hospital 

CLOVES Syndrome Community committed to support a project looking for risk factors predicting common complications in CLOVES, using data from the 127 patients with CLOVES in the Lymphatic Anomalies Registry ( 

Make a Donation

Your contribution will help our organization be strong and sustainable for many years to come.


“Never doubt that a small group of thoughtful, committed citizens can change the world; indeed, it’s the only thing that ever has.”
– Margaret Mead